<DOC>
	<DOC>NCT00526071</DOC>
	<brief_summary>This is a long term open label study of AT1001 in patients with Fabry disease previously enrolled in a Phase 2 AT1001 trial.</brief_summary>
	<brief_title>Open Label Long-term Safety Study of AT1001 in Patients With Fabry Disease Who Have Completed a Previous AT1001 Study</brief_title>
	<detailed_description>This is a long term open label study of AT1001 in patients with Fabry disease previously enrolled in a Phase 2 AT1001 trial. Patients will return to the study center approximately every 3 months for safety evaluations including physical exam, blood and urine tests.</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>1. Must have completed another Phase 2 trial of AT1001 in Fabry Disease 2. Women of childbearing potential must have negative pregnancy result 3. Male and Female subjects agree to use reliable method of contraception during treatment and four weeks after treatment has completed. 4. Subject is willing and able to provide written informed consent 1. Subject did not complete Phase 2 trial of AT1001 in Fabry Disease 2. Has undergone or is scheduled to undergo kidney transplantation or is currently on dialysis 3. Has been treated with another investigational drug (except AT1001) within 30 days of study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Fabry Disease</keyword>
	<keyword>Lysosomal Storage Disorder</keyword>
</DOC>